Sanofi-Aventis publishes Jevtana prostate cancer trial in The Lancet
This article was originally published in Scrip
Executive Summary
The Phase III TROPIC trial of Sanofi-Aventis's new chemotherapy drug, Jevtana (cabazitaxel), has just been published in The Lancet.